亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

医学 皮调节素 药代动力学 安非雷古林 抗体-药物偶联物 内科学 表皮生长因子受体 药理学 不利影响 单克隆抗体 抗体 肿瘤科 胃肠病学 癌症 免疫学
作者
James M. Cleary,Emiliano Calvo,Víctor Moreno,Dejan Juric,Geoffrey Ira Shapiro,Carol Ann Vanderwal,Beibei Hu,Maryella Gifford,David Barch,Lisa A. Roberts-Rapp,Peter J. Ansell,Hao Xiong,Christopher Joseph Ocampo,Anthony W. Tolcher
出处
期刊:Investigational New Drugs [Springer Science+Business Media]
卷期号:38 (5): 1483-1494 被引量:37
标识
DOI:10.1007/s10637-020-00908-3
摘要

Losatuxizumab vedotin (formerly ABBV-221) is a second-generation antibody-drug conjugate targeting epidermal growth factor receptor (EGFR). In this multicenter phase 1 study, eligible patients with EGFR-dependent solid tumors received losatuxizumab vedotin (3 + 3 design) intravenously at starting dose of 0.3 mg/kg over 3 h per 21-day cycle, with alternate dosing schedules utilized (2 weeks on/1 week off or weekly) to mitigate infusion reactions. Forty-five patients received ≥1 doses of losatuxizumab vedotin (13 colon, 6 non-small cell lung cancer, 5 head and neck [HNC], 5 glioblastoma multiforme, 2 breast, 14 other). Tumor samples were evaluated for EGFR protein expression by immunohistochemistry, EGFR and EGFR ligand mRNA expression by RNAseq, and results compared with outcome. Most common adverse events were infusion-related reaction (22/45; 49%) and fatigue (20/45; 44%). While most infusion reactions were grade ≤ 2, four patients experienced grade ≥3 infusion reactions. Several infusion reaction mitigation strategies were explored. Because of the high incidence of infusion reactions, the trial was stopped and the maximum tolerated dose was not reached. The last cleared dose: 6 mg/kg/cycle. Nineteen patients (42%) had stable disease; 4 remained on study >6 months. One HNC patient with increased levels of EGFR and EGFR ligands (amphiregulin, epiregulin) achieved a confirmed partial response. Pharmacokinetic analysis of losatuxizumab vedotin showed exposures appeared to be approximately dose-proportional. The high frequency of infusion reactions necessitated early closure of this trial. The detailed mitigation strategies used in this protocol for infusion-related reactions may provide beneficial information for trial design of agents with high infusion reaction rates.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
第二支羽毛完成签到,获得积分10
5秒前
7秒前
共享精神的应助被科研通管家采纳,获得10
7秒前
7秒前
null的应助被科研通管家采纳,获得10
7秒前
可爱的函函的应助被Drunk采纳,获得10
7秒前
11秒前
祎辰完成签到 ,获得积分10
14秒前
现代的如容完成签到,获得积分10
18秒前
lyp完成签到 ,获得积分10
22秒前
23秒前
平和的狍子完成签到 ,获得积分10
25秒前
汉堡包的应助被breeze采纳,获得10
28秒前
Akim的应助被Yuantian采纳,获得30
29秒前
30秒前
乐正亦寒完成签到 ,获得积分10
36秒前
酷炫鹏煊完成签到 ,获得积分10
38秒前
学霸宇大王完成签到 ,获得积分10
43秒前
淡然葶完成签到 ,获得积分10
43秒前
黑早早完成签到,获得积分10
43秒前
谦让的沛芹完成签到,获得积分10
45秒前
46秒前
47秒前
48秒前
51秒前
58秒前
59秒前
liugm发布了新的文献求助10
1分钟前
toxin37完成签到 ,获得积分10
1分钟前
小井盖完成签到 ,获得积分0
1分钟前
1分钟前
含蓄的芝麻完成签到,获得积分10
1分钟前
陌陌完成签到 ,获得积分10
1分钟前
菌菌的应助被郦稀采纳,获得30
1分钟前
1分钟前
煊陌完成签到 ,获得积分10
1分钟前
xiaoyin完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
Lifel完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277